Case Report: Toxic epidermal necrolysis induced by sintilimab in a patient with advanced lung squamous cell carcinoma

Key Points

• Toxic epidermal necrolysis developed following sintilimab administration in one patient.
• Monitoring for skin reactions is critical during immune checkpoint inhibitor therapy.
• Case emphasizes the serious risks in advanced lung squamous cell carcinoma treatment with sintilimab.
• Immediate intervention may be necessary to address severe adverse effects associated with therapy.

Abstract